Inventor · disambiguated record
Heinz Lubenau
Also filed as: LUBENAU HEINZ
15 granted patents·9 pending applications·58 citations·filing 2008–2022
91Inventor score
Top patents by PatentIndex Score
24 records- 0196US11590215B2Process for the production of a DNA vaccine for cancer immunotherapyVAXIMM AG·Filed 2020·Granted Feb 28, 2023·6 cites·7 claims
- 0295US10293037B2DNA vaccine for use in pancreatic cancer patientsVAXIMM AG·Filed 2018·Granted May 21, 2019·10 cites·18 claims
- 0394US9415098B2DNA vaccine for use in pancreatic cancer patientsVAXIMM AG·Filed 2013·Granted Aug 16, 2016·17 cites·14 claims
- 0492US10821163B2Process for the production of a DNA vaccine for cancer immunotherapyVAXIMM AG·Filed 2017·Granted Nov 3, 2020·7 cites·13 claims
- 0584US10980868B2VEGFR-2 targeting immunotherapy approachVAXIMM AG·Filed 2018·Granted Apr 20, 2021·2 cites·21 claims
- 0683US10815455B2Salmonella-based vectors for cancer immunotherapy targeting Wilms' tumor gene WT1VAXIMM AG·Filed 2018·Granted Oct 27, 2020·3 cites·14 claims
- 0781US10441645B2MSLN targeting DNA vaccine for cancer immunotherapyVAXIMM GMBH·Filed 2017·Granted Oct 15, 2019·3 cites·12 claims
- 0877US10905752B2VEGFR-2 targeting DNA vaccine for combination therapyVAXIMM AG·Filed 2016·Granted Feb 2, 2021·1 cites·8 claims
- 0975US9920297B2Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene WT1VAXIMM AG·Filed 2014·Granted Mar 20, 2018·3 cites·15 claims
- 1072US9050304B2Methods of treatment using glycopegylated G-CSFZOPF DAVID A·Filed 2008·Granted Jun 9, 2015·3 cites·37 claims
- 1172US8562967B2Stable liquid formulations of G-CSFHINDERER WALTER·Filed 2008·Granted Oct 22, 2013·1 cites·25 claims
- 1269US8946161B2Method of treatment using stable liquid formulation of G-CSFBIOGENERIX GMBH·Filed 2013·Granted Feb 3, 2015·2 cites·12 claims
- 1367US2022273782A1Novel PD-L1 Targeting DNA Vaccine for Cancer ImmunotherapyVAXIMM AG·Filed 2022·Application pending·0 cites
- 1464US11357842B2PD-L1 targeting DNA vaccine for cancer immunotherapyVAXIMM AG·Filed 2018·Granted Jun 14, 2022·0 cites·14 claims
- 1561US2021077605A1Vegfr-2 targeting dna vaccine for combination therapyVAXIMM AG·Filed 2020·Application pending·0 cites
- 1658US2016250311A1Dna vaccine for use in pancreatic cancer patientsVAXIMM AG·Filed 2016·Application pending·0 cites
- 1755US2016317634A1Novel msln targeting dna vaccine for cancer immunotherapyVAXIMM GMBH MAFINEX-TECHNO-LOGIEZENTRUM·Filed 2014·Application pending·0 cites
- 1854US2023137174A1Novel salmonella-based coronavirus vaccineNEC ONCOIMMUNITY AS·Filed 2021·Application pending·0 cites
- 1953US2023121528A1Salmonella-based dna vaccines in combination with an antibioticVAXIMM AG·Filed 2021·Application pending·0 cites
- 2049US9468685B2Methods of preparing a liquid formulation of G-CSFRATIOPHARM GMBH·Filed 2015·Granted Oct 18, 2016·0 cites·13 claims
- 2146US2021213121A1Neoantigen targeting dna vaccine for combination therapyVAXIMM AG·Filed 2019·Application pending·0 cites
- 2239US2023158133A1Wt1 targeting dna vaccine for combination therapyVAXIMM AG·Filed 2017·Application pending·0 cites
- 2337US9493738B2Method for producing high yield attenuated Salmonella strainsVAXIMM AG·Filed 2012·Granted Nov 15, 2016·0 cites·15 claims
- 2437US2018153976A1Novel cmv pp65 targeting dna vaccine for cancer immunotherapyVAXIMM AG·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Heinz Lubenau files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →